Bml , Inc. · TSE:4694
Bml — FY2025 Earnings Presentation
43 slides from Bml's earnings presentation, May 13, 2026
Slide 1: Financial Results Presentation for Fiscal 2025
BML Inc. Financial Results Presentation for Fiscal 2025 May 13, 2026 Kensuke Kondo, President and Representative Director
Slide 2: Contents
Contents Overview of Fiscal 2025 Progress of the Ninth Medium-Term Management Plan Progress of Capital and Business Alliance with FALCO HOLDINGS Co., Ltd. Full-Year Forecast for FY2026 Allocation of Cash, Shareholder Returns 1
Slide 3: Overview of Fiscal 2025
Overview of Fiscal 2025 2 2
Slide 4: Earnings History in 10 Years
Earnings History in 10 Years Increase in net sales and profit reflecting efforts to acquire new customers and improve profitability Net sales Operating profit (Millions of yen) (Millions of yen) 4.9% (>4.0%) growth from FY2024 FY2025 3
Slide 5: Year-on-Year Comparison
Year-on-Year Comparison (Millions of yen) FY2024 FY2025 YoY Change Net sales 143,191 150,262 7,071 4.9% Testing business 136,219 143,191 6,971 5.1% Clinical testing 130,925 137,661 6,735 5.1% Food hygiene 5,294 5,530 235 4.5% Medical informatics 5,478 5,524 46 0.8% Other businesses 1,493 1,546 53 3.
Slide 6: Breakdown of Changes in Sales by Business Segment
Breakdown of Changes in Sales by Business Segment Net sales up ¥7,071m (4.9%) YoY (Millions of yen) +235 +46 +53 +6,735 Medical Other Food hygiene informatics businesses business business Clinical testing business 5
Slide 7: Breakdown of Changes in Operating Profit by Business Segment
Breakdown of Changes in Operating Profit by Business Segment Operating profit up \1,057m (11.3％) YoY (Millions of yen) +124 -122 +18 -209 +1,245 Food Medical Other Company- hygiene informatics businesses wide business business Clinical testing business 6
Slide 8: Overview of Clinical Testing Business
Overview of Clinical Testing Business Net sales: \137,661m Up \6,735m (5.1％) YoY Major topics (Millions of yen) ✓ New acquisitions ・Steady acquisition of new customers 130,925 137,661 126,454 ✓ Promotion of price optimization ・Review of unprofitable items and customers ✓ Price fluctuations ・Increase
Slide 9: Overview of Food Hygiene and Other Testing Business
Overview of Food Hygiene and Other Testing Business Net sales: \5,530m Up \235m (4.5％) YoY Major topics (Millions of yen) ✓ Promoting transaction terms optimization ・ Implemented an optimization of store 5,294 5,530 inspection unit prices primarily for major 5,019 customers ✓ Food consulting ・ Incre
Slide 10: Overview of Medical Informatics (Electronic Patient Chart) Business
Overview of Medical Informatics (Electronic Patient Chart) Business Net sales: \5,524m Up \46m (0.8％) YoY Major topic (Millions of yen) ✓ Replacements ・ Steady response to replacement demand 5,478 5,524 4,874 9
Slide 11: Overview of Other Businesses
Overview of Other Businesses Net sales: \1,546m Up \53m (3.6%) YoY Major topics (Millions of yen) 1,616 ✓ Dispensing pharmacy business 1,493 1,546 ・ Increase in prescription of high-priced drugs ✓ Site management organization (SMO) services for clinical trials at medical institutions ・ Increase in t
Slide 12: Overview of Capital Expenditure and Depreciation
Overview of Capital Expenditure and Depreciation Capital expenditure (Millions of yen) Investment related to Investment new buildings related to 15,602 new buildings Investment 10,867 related to new buildings 3,629 Depreciation (Millions of yen) 11
Slide 13: Overview of Cash Flow
Overview of Cash Flow (Millions of yen) FY2024 FY2025 YoY Cash flows from operating activities 15,809 20,715 4,906 Cash flows from investing activities (16,793) (7,689) 9,104 Cash flows from financing activities (5,426) (12,351) (6,925) Cash and cash equivalents at end of period 63,928 64,602 673 ■
Slide 14: Progress of the Ninth Medium-Term Management Plan
Progress of the Ninth Medium-Term Management Plan 13
Slide 15: Vision
Vision ■ Stable sales growth ■ Achieve a rapid increase in revenue through the effects of the new buildings, DX, and price strategies ■ Balance between growth investment and shareholder returns Net sales Net sales \160 \200 billion billion *Excluding COVID-19-related testing Net sales Net sales EBIT
Slide 16: Basic Strategic Frameworks
Basic Strategic Frameworks Expanding sales and Enhanced quality market Enhancing share Promoting the level of standardization service Development of next- Solutions generation laboratories Development Optimizing of high- the business performance tests portfolio Mutual development Improving profitabi
Slide 17: Development of Next-generation Laboratories
Development of Next-generation Laboratories Expanding sales and market Enhancing the level of share Promoting standardization Road map service Development of next- generation ■ Phase 1: BCP / environmental measures and testing capacity Development laboratories Optimizing the business expansion in co
Slide 18: Development of Next-generation Laboratories: Testing Capacity Extension
Development of Next-generation Laboratories Expanding ■ Extension of testing capacity with completion of the new sales and Enhancing market share Promoting building the level of standardization service Development of next- Expansion of testing capacity to 140%–150% of the FY2023 generation laborator
Slide 19: Development of Next-generation Laboratories: Revised FY2026 Capacity Outlook
Development of Next-generation Laboratories Expanding ■ Revision of the FY2026 outlook for testing capacity sales and market Enhancing share Promoting The Frontier (pre-analytical processing) and Chemistry (biochemistry) the level of standardization service Development areas are expected to come on
Slide 20: Development of Next-generation Laboratories: Depreciation Timing
Development of Next-generation Laboratories Expanding ■ The earlier start of equipment operation will accelerate the sales and Enhancing market share Promoting timing of depreciation recognition the level of standardization service Development Original plan: Peak depreciation in FY2027 of next- gene
Slide 21: Improving Profitability: Cost Reduction
Improving Profitability Expanding ■ Cost reduction through new building construction Steady progress made in cutting \1,000m of costs across the sales and market Enhancing share Promoting the level of standardization processes from reception to reporting service Development of next- generation Key i
Slide 22: Improving Profitability: Clinical Testing Business
Improving Profitability Expanding ■ Radically improve the profitability of the clinical testing business sales and market Profitability improvement: Steady progress made toward achieving a Enhancing the level of share Promoting standardization ¥4,000m profit improvement service Development of next-
Slide 23: EBITDA Margin
EBITDA Margin ■ Profitability improvement plan EBITDA margin on the rise after bottoming out in FY2023 Aim to recover the pre-COVID-19 pandemic level Changes in the EBITDA margin Up 1.5 points COVID-19 pandemic 22
Slide 24: Changes in Management Indicators
Changes in Management Indicators Target EBITDA margin COVID-19 pandemic Operating profit margin Target COVID-19 pandemic ROE Target COVID-19 pandemic 23
Slide 25: Expanding Sales and Market Share: Food Hygiene Testing Base
Expanding Sales and Market Share Expanding ■ Transfer and expansion of the Food Hygiene Testing sales and Enhancing market share Promoting Business base the level of standardization service Development Testing capacity in the Hokkaido region expanded to 130% of of next- generation laboratories the p
Slide 26: Expanding Sales and Market Share: Pathological Testing Bases
Expanding Sales and Market Share Expanding ■ Transfer and expansion of pathological testing bases sales and market Expansion of testing capacity in the Tohoku region Enhancing share Promoting the level of service Development standardization Successive investments in each region to expand market shar
Slide 27: Human Capital Investment
Human Capital Investment Expanding ■ Strategic securing of highly skilled specialists sales and market Raising the level of specialist expertise Enhancing share Promoting the level of Standardization → Supplementing specialist knowledge and skills that are service Development of next- lacking intern
Slide 28: DX Initiatives: B-Label
DX Initiatives Expanding ■ Reduction of delivery-related operation with B-Label* sales and Enhancing market share Promoting Streamlining delivery-related operations through expanded use of the level of service Standardization B-Label Development of next- generation → Number of B-Label specimens incr
Slide 29: DX Initiatives: On-line Test Requests
DX Initiatives Expanding ■ Promotion of on-line test requests* sales and market Enhancing share Promoting Customers: The work of making requests and the risk of personal the level of Standardization service Development information leaks can be reduced of next- generation BML: Burden of the work in r
Slide 30: DX Initiatives: DX Investment
DX Initiatives Expanding ■ DX investment sales and market Enhancing the level of share Promoting Standardization Total investment under the 10-year strategy is projected at ¥10,000m service Development of next- → Investment in IT infrastructures: ¥6,000m generation laboratories Optimizing → DX promo
Slide 31: Progress of Capital and Business Alliance with FALCO HOLDINGS Co., Ltd.
Progress of Capital and Business Alliance with FALCO HOLDINGS Co., Ltd. 30 30
Slide 32: Progress of Capital and Business Alliance with FALCO HOLDINGS Co., Ltd.
Progress of Capital and Business Alliance with FALCO HOLDINGS Co., Ltd. Business alliance progress FALCO HOLDINGS → BML BML → FALCO HOLDINGS Contracting of specialized testing items Sale of ICT products Transfer of some 400 items that had been initially Introduced Falco’s ICT product (Recesta) to pl
Slide 33: Full-Year Forecast for FY2026
Full-Year Forecast for FY2026 32
Slide 34: Full-Year Forecast for FY2026
Full-Year Forecast for FY2026 ■ Fiscal year in which depreciation related to the new building will peak ■ Cost increases are anticipated due to price rises driven by the situation in the Middle East (Millions of yen) FY2026 FY2025 forecast YoY Change Net sales 150,262 155,000 4,738 3.2% Testing busi
Slide 35: Allocation of Cash, Shareholder Returns
Allocation of Cash Shareholder Returns 34
Slide 36: Allocation of Cash
Allocation of Cash ■ In the Ninth Medium-Term Management Plan, seek to further strengthen growth-oriented investment and investment in infrastructure as well as shareholder return using internal reserve in addition to cash flows from operating activities (CFFO) ■ Within growth-oriented investment in
Slide 37: Shareholder Returns
Shareholder Returns ■ Return policy in the Ninth Medium-Term Management Plan ・Payout ratio of 60% or higher, and ¥120 or more per share ■ Annual dividend in the fiscal year ended March 31, 2026, is projected at ¥125 per share of ordinary stock (year-end dividend +¥5) (Payout ratio forecast for FYE M
Slide 38: Appendix
Appendix 37 37
Slide 39: ESG Initiatives: Kurumin and Eruboshi Certifications
ESG Initiatives Social ■ Received “Platinum Kurumin” certification → As part of our efforts to promote Diversity, Equity & Inclusion, we are active encouraging male employees to take parental leave, providing support to employees returning from childcare leave, and helping employees balance post-lea
Slide 40: ESG Initiatives: Health and Productivity Management
ESG Initiatives Health and productivity management ■ BML Health Declaration “Dedication to creating a healthy and cultured society” To realize this corporate philosophy, the BML Group declares its dedication to contribute to the creation of a healthy and cultured society with each and every employee
Slide 41: ESG Initiatives: Health and Productivity KPIs
ESG Initiatives Health and productivity management ■ The Company has set KPIs and targets for each under the supervision of occupational physicians, and is working to achieve these targets. Evaluation indicator FY2021 FY2022 FY2023 FY2024 2026 target Percentage of employees receiving regular health
Slide 42: 41
41
Slide 43: Cautions Regarding Use of This Document
Cautions Regarding Use of This Document <Cautions regarding forward-looking statements, etc.> Forward-looking statements contained in this document, such as projections, strategies and plans, are based on the Company’s judgment formed on the basis of various assumptions made at the time of preparati